Perimeter Medical Imaging AI Names Noted Oncologist as Chief Medical Officer

Perimeter Medical Imaging AI Inc. (TSX-V: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company based in Dallas and Toronto, Canada, has appointed noted surgical oncologist Ted James to the newly created position of chief medical officer.

“Dr. James brings a unique combination of clinical experience, research leadership, and insight into how care is delivered,” Perimeter CEO Adrian Mendes said in a statement. “His expertise will be invaluable as we work to demonstrate the medical and practical value of our next-generation, AI-enabled Perimeter B-Series and advance it toward FDA approval.”

In this fractional role, James will bring his clinical and leadership experience to help Perimeter strengthen its medical strategy and accelerate adoption of its technology, the company said. It said that James’ perspective as a cancer surgeon and health system executive, combined with his experience in healthcare innovation, will support the company’s growth as it advances toward commercialization.

Recently, James became System Physician Executive of the Endeavor Health Cancer Institute after serving as chief of breast surgical oncology and director of the Breast Center at Beth Israel Deaconess Medical Center (BIDMC), where he oversaw the growth of a nationally accredited multidisciplinary breast program and developed an NIH-funded research portfolio.

James also was vice chair of academic affairs in the Department of Surgery at BIDMC and an Associate Professor of Surgery at Harvard Medical School.

“It’s a privilege to join Perimeter at such a pivotal time,” James said. “I have spent much of my career working on ways to improve breast cancer surgery, and margin assessment has always been a challenging problem to solve. What excites me about Perimeter is the chance to put a practical tool in the hands of surgeons that can make a real difference in the operating room. I’m looking forward to helping the team bring this technology to the patients who need it.”

Perimeter Medical Imaging AI said it is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

Available across the U.S., its FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents the company’s next-generation artificial intelligence technology that has recently been evaluated in a pivotal clinical trial, with support from a grant of up to $7.4 million awarded by the Cancer Prevention and Research Institute of Texas.